Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Language
Publication year range
1.
Acta Otorrinolaringol Esp ; 56(2): 83-5, 2005 Feb.
Article in Spanish | MEDLINE | ID: mdl-15782648

ABSTRACT

Frey syndrome has been observed especially in patients who have undergone a parotidectomy operation, but also in zoster herpes, in parotiditis, condilea fractures, obstetric traumatisms with forceps and in surgery of the meningioma of the cerebellopontine angle. It also appears without previous surgery, like in our case. In these circumstances it is believed that a clinical neuritis, primary or secondary to a neighbouring inflammation may cause the start of this disorder. Several treatments have been suggested which highlights the difficulty of them. The most effective one is the intradermic injection of botulinum toxin type A. Its use in Frey's syndrome was initiated by Drobik and Laskawi in 1995. Since then the references to its use are numerous. Nevertheless, it is a treatment which has been introduced very few times in our country.


Subject(s)
Botulinum Toxins, Type A/therapeutic use , Neuromuscular Agents/therapeutic use , Otitis Externa/diagnosis , Sweating, Gustatory/diagnosis , Aged , Botulinum Toxins, Type A/administration & dosage , Diagnosis, Differential , Humans , Injections, Intradermal , Male , Neuromuscular Agents/administration & dosage , Recurrence , Sweating, Gustatory/drug therapy
2.
Acta otorrinolaringol. esp ; 56(2): 83-85, feb. 2005. ilus
Article in Es | IBECS | ID: ibc-038140

ABSTRACT

El síndrome de Frey se ha observado sobre todo en pacientes sometidos a parotidectomía, pero también en el herpes zoster trigeminal, en las parotiditis, en las fracturas condíleas, en los traumatismos obstétricos con forceps y en la cirugía del meningioma del ángulo ponto-cerebeloso. También aparece sin cirugía previa, como es nuestro caso. En estas circunstancias se piensa que una neuritis subclínica, primaria o secundaria a una inflamación vecina, puede causar el inicio de este trastorno. Se han propuesto varios tratamientos, lo cual pone de manifiesto la dificultad del mismo. El más eficaz es la inyección de toxina botulínica tipo A intradérmica. Su manejo en el síndrome de Frey lo iniciaron Drobik y Laskawi en 1995. Desde entonces son numerosas las referencias sobre su manejo. Sin embargo, es un tratamiento aún poco difundido en nuestro país


Frey syndrome has been observed especially in patients who have undergone a parotidectomy operation, but also in zoster herpes, in parotiditis, condilea fractures, obstetric traumatisms with forceps and in surgery of the meningioma of the cerebellopontine angle. It also appears without previous surgery, like in our case. In these circumstances it is believed that a clinical neuritis, primary or secondary to a neighbouring inflammation may cause the start of this disorder. Several treatments have been suggested which highlights the difficulty of them. The most effective one is the intradermic injection of botulinum toxin type A. It’s use in Frey’s syndrome was initiated by Drobik and Laskawi in 1995. Since then the references to its use are numerous. Nevertheless, it is a treatment which has been introduced very few times in our country


Subject(s)
Male , Aged , Humans , Botulinum Toxins, Type A/therapeutic use , Neuromuscular Agents/therapeutic use , Otitis Externa/diagnosis , Botulinum Toxins, Type A/administration & dosage , Diagnosis, Differential , Injections, Intradermal , Neuromuscular Agents/administration & dosage , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL
...